Blood coagulation is the process that includes the forming of the blood clot. The blood clot formation is often referred to as secondary hemostasis as it forms the second stage in the process of preventing the loss of blood from a ruptured vessel. Hemostasis is the mechanism of clotting that involves activation, adhesion, and aggregation of platelets mediated by a number of clotting factors, eventually leading to the repairing of the injured tissue. Any problem or absence of any of these factors potentially leads to a rare but severe blood clotting disease and excessive bleeding.
MARKET SCOPE
The "Blood Coagulation Factor Market to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of blood coagulation factor market with detailed market segmentation by of product, labeling method, application. The blood coagulation factor market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in blood coagulation factor market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- n the basis of product type, the market is segmented into Product and Servi Factor VII, Factor VIII, Factor IX, Factor X, Factor XIII, Von Willebrand Factor and Anti-Inhibitor Coagulant Complex.
- n the basis of application, the market is segmented into Haemophilia, Von Willebrand Disorder, Surgery and others.
- n the basis of technology, the market is segmented into Plasma Derived, Recombinant.
MARKET DYNAMICS
Drivers:
- Increase in consciousness and rapid development in healthcare expenditure.
- Growing occurrences of lifestyle-related conditions such as diabetes, obesity, and cardiovascular disorders.
- Developing healthcare infrastructure.
Restraints:
- Severe regulatory policies and a shortage in plasma supply can hinder the market growth.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the blood coagulation factor market based on various segments. It also provides market size and forecast estimates from year 2021 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The blood coagulation factor market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting blood coagulation factor market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting blood coagulation factor market in these regions.
IMPACT OF COVID-19 ON BLOOD COAGULATION FACTOR MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. The global impacts of the COVID-19 are already starting to be felt, and will significantly affect the blood coagulation factor market in 2020.Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the blood coagulation factor market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from blood coagulation factor market are anticipated to have lucrative growth opportunities in the future with the rising demand for blood coagulation factor market in the global market. Below mentioned is the list of few companies engaged in the blood coagulation factor market.
The report also includes the profiles of key players in blood coagulation factor market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.
- Pfizer
- Baxter
- Octapharma AG
- Novo Nordisk
- Grifols, S.A.
- CSL Behring
- Shire (Takeda Pharmaceutical Company Limited)
- Biogen Idec
- Kedrion Biopharma Inc.
- F. Hoffmann-La Roche Ltd